Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01795313 · ClinicalTrials.gov registry record · Phase 1
Immunotherapy for Recurrent Ependymomas in Children Using Tumor Antigen Peptides With Imiquimod
A Phase 1 study, sponsored by James Felker.
- Terminated
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT01795313 is a Phase 1 study that was terminated before completion, run by James Felker. The registered enrollment target is 23 participants.
The verdict
NCT01795313, a Phase 1 study, was terminated before completion, sponsored by James Felker.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
The purpose of this study is to see if vaccination with HLA-A2 restricted peptides, combined with the immunoadjuvant imiquimod is safe and can induce immune responses in children with recurrent ependymomas. Eligible patients are stratified by primary tumor location.
Interventions
- DRUG Imiquimod
- OTHER immunohistochemistry staining method
- OTHER flow cytometry
- OTHER enzyme-linked immunosorbent assay
- BIOLOGICAL HLA-A2 restricted synthetic tumor antigen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2012-08 |
| Est. Completion | 2025-12-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01795313
The ClinicalTrials.gov registry entry for NCT01795313 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is James Felker, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Imiquimod is the first listed.
NCT01795313 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01795313 about?
NCT01795313 is a clinical study titled "Immunotherapy for Recurrent Ependymomas in Children Using Tumor Antigen Peptides With Imiquimod". The purpose of this study is to see if vaccination with HLA-A2 restricted peptides, combined with the immunoadjuvant imiquimod is safe and can induce immune responses in children with recurrent ependymomas. Eligible patients are stratified by primary tumor location.
What is the current status of trial NCT01795313?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2012-08. Estimated completion is 2025-12-03.
What interventions are being tested in trial NCT01795313?
The interventions under investigation include: Imiquimod (DRUG), immunohistochemistry staining method (OTHER), flow cytometry (OTHER), enzyme-linked immunosorbent assay (OTHER), HLA-A2 restricted synthetic tumor antigen (BIOLOGICAL).
Who is sponsoring clinical trial NCT01795313?
This trial is sponsored by James Felker, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.